Reproductive characteristics in relation to ovarian cancer risk by histologic pathways

Human Reproduction

Volumn 28, Issue 5, 2013, Pages 1406-1417

  Merritt, M A ^a,b,c   De Pari, M ^b   Vitonis, A F ^b   Titus, L J ^d   Cramer, D W ^a,b   Terry, K L ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

histology; ovarian cancer; reproduction; risk factors; type I II

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; ENDOMETRIOSIS; FAMILY HISTORY; FEMALE; HISTOLOGY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MENARCHE; OVARY CANCER; OVARY CARCINOMA; REPRODUCTIVE HEALTH; RISK ASSESSMENT; UTERINE TUBE LIGATION;

EID: 84876567104     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/des466     Document Type: Article

References (59)

1. Adami H, Hsieh C, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson P. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344: 1250-1254. (Pubitemid 24334680)
2. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221: 49-56.
3. Baik I, Lambe M, Liu Q, Cnattingius S, Mucci LA, Riman T, Ekbom A, Adami HO, Hsieh CC. Gender of offspring and maternal risk of invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 2314-2320. (Pubitemid 351196363)
4. Bulun SE. Endometriosis. N Engl J Med 2009;360: 268-279.
5. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004;64: 7678-7681. (Pubitemid 39446895)
6. Chiaffarino F, Parazzini F, Bosetti C, Franceschi S, Talamini R, Canzonieri V, Montella M, Ramazzotti V, La Vecchia C. Risk factors for ovarian cancer histotypes. Eur J Cancer 2007;43: 1208-1213. (Pubitemid 46590735)
7. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011;17: 55-67.
8. Cramer D, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71: 717-721. (Pubitemid 14232385)
9. Cuatrecasas M, Erill N, Musulen E, Costa I, Matias-Guiu X, Prat J. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer 1998; 82: 1088-1095. (Pubitemid 28136522)
10. Fathalla MF. Incessant ovulation- A factor in ovarian neoplasia? Lancet 1971;2: 163.
11. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010;171: 45-53.
12. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003;90: 378-381. (Pubitemid 36952030)
13. Glynn RJ, Rosner B. Methods to evaluate risks for composite end points and their individual components. J Clin Epidemiol 2004;57: 113-122. (Pubitemid 38678613)
14. Harris HR, Cramer DW, Vitonis AF, Depari M, Terry KL. Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 2012;131: E518-E529.
15. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H et al. (eds) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). http://seer.cancer.gov/csr/1975-2009- pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
16. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, Uchida K, Miwa M. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994;54: 33-35. (Pubitemid 24042083)
17. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008;53: 127-138. (Pubitemid 352032762)
18. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330: 228-231.
19. Jordan SJ, Green AC, Whiteman DC, Moore SP, Bain CJ, Gertig DM, Webb PM. Serous ovarian, Fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 2008; 122: 1598-1603. (Pubitemid 351294969)
20. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31: 161-169. (Pubitemid 46175016)
21. King SM, Hilliard TS, Wu LY, Jaffe RC, Fazleabas AT, Burdette JE. The impact of ovulation on Fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer. Endocr Relat Cancer 2011;18: 627-642.
22. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005;96: 520-530. (Pubitemid 40127159)
23. Kurman RJ, Shih l. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011; 42: 918-931.
24. Lambe M, Wuu J, Rossing MA, Hsieh CC. Twinning and maternal risk of ovarian cancer. Lancet 1999;353: 1941. (Pubitemid 29255716)
25. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW et al. A candidate precursor to serous carcinoma that originates in the distal Fallopian tube. J Pathol 2007;211: 26-35. (Pubitemid 46092026)
26. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005;14: 98-107. (Pubitemid 40165289)
27. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61: 152-163. (Pubitemid 351218874)
28. Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark 2010;9: 287-305.
29. Missmer SA, Chavarro JE, Malspeis S, Bertone-Johnson ER, Hornstein MD, Spiegelman D, Barbieri RL, Willett WC, Hankinson SE. A prospective study of dietary fat consumption and endometriosis risk. Hum Reprod 2010;25: 1528-1535.
30. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001;11: 568-574. (Pubitemid 33049892)
31. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002;13: 807-811. (Pubitemid 35305199)
32. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001;10: 116-122. (Pubitemid 32525880)
33. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC. Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 2008;44: 2477-2484.
34. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58: 2095-2097. (Pubitemid 28232892)
35. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13: 385-394.
36. Pelucchi C, Caleone C, Talamini R, Bosetti C, Montella M, Negri E, Franceschi S, La Vecchia C. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 2007; 196: 83.e1-83.e7.
37. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-456. (Pubitemid 33069670)
38. Purdie D, Siskind V, Bain C, Webb PM, Green A. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001;153: 860-864. (Pubitemid 32378619)
39. Purdie DM, Bain CJ, Siskind V,Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104: 228-232. (Pubitemid 36249799)
40. Rice MS, Murphy MA, Tworoger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 2012;5: 13.
41. Riman T, Nilsson S, Persson IR. Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 2004;83: 783-795. (Pubitemid 39179432)
42. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90: 1774-1786. (Pubitemid 28559889)
43. Risch H, Marrett L, Jain M, Howe G. Differences in risk factors for epithelial ovarian cancer by histologic type: results of a case-control study. Am J Epidemiol 1996;144: 363-372. (Pubitemid 26262199)
44. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5: 271-276. (Pubitemid 28427517)
45. Shih L, Kurman R. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-1518. (Pubitemid 38529752)
46. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95: 484-486. (Pubitemid 36432423)
47. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007;16: 1160-1166. (Pubitemid 46984953)
48. Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006;101: 331-341. (Pubitemid 44262088)
49. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 2005;161: 442-451. (Pubitemid 40315615)
50. Terry KL, Titus-Ernstoff L, McKolanis JR, Welch WR, Finn OJ, Cramer DW. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 30-35. (Pubitemid 46174260)
51. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474: 609-615.
52. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158: 629-638. (Pubitemid 37175510)
53. Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, Terada KY, Goodman MT. Effect of anovulation factors on pre-and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol 2005;161: 321-329. (Pubitemid 40256203)
54. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136: 1184-1203. (Pubitemid 23026890)
55. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE et al. ARID1A mutations in endometriosis- associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
56. Wittenberg J, Cook LS, Rossing MA, Weiss NS. Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 1999;10: 761-763. (Pubitemid 29494059)
57. Wu R, Zhai Y, Fearon ER, Cho KR. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 2001;61: 8247-8255. (Pubitemid 33091619)
58. Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012;25: 615-624.
59. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer 2011;131: 938-948.